ALLURION TECHNOLOGIES INC (ALUR) Stock News
NYSE:ALUR - New York Stock Exchange, Inc. - US02008G2012 - Common Stock - Currency: USD
ALUR Latest News, Press Relases and Analysis
Wednesday's pre-market session: top gainers and losers
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Top movers in Tuesday's after hours session
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates
Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of 128.10% and 2.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MDT
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of 39.84% and 5.54%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ICUI
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -80% and 4.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: EOLS
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Allurion Announces Postponement of Special Meeting of Stockholders
Allurion Stock Tumbles Over Disappointing Quarterly Earnings, Revenue Guidance – But Retail’s Not Concerned
Allurion attributed the fall in Q4 revenue to a temporary suspension of sales in France, coupled with macroeconomic headwinds in certain markets, which caused lower reorder rates.
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
